| Literature DB >> 28949064 |
Marc van Bilsen1, Hitesh C Patel2,3,4, Johann Bauersachs5, Michael Böhm6, Martin Borggrefe7,8, Dirk Brutsaert9, Andrew J S Coats10,11, Rudolf A de Boer12, Gilles W de Keulenaer13, Gerasimos S Filippatos14, John Floras15, Guido Grassi16,17, Ewa A Jankowska18,19, Lilian Kornet20, Ida G Lunde21, Christoph Maack6, Felix Mahfoud6, Piero Pollesello22, Piotr Ponikowski18,19, Frank Ruschitzka23, Hani N Sabbah24, Harold D Schultz25, Petar Seferovic26, Riemer H J A Slart27,28, Peter Taggart29, Carlo G Tocchetti30, Linda W Van Laake31, Faiez Zannad32,33, Stephane Heymans34,35, Alexander R Lyon2,3.
Abstract
Despite improvements in medical therapy and device-based treatment, heart failure (HF) continues to impose enormous burdens on patients and health care systems worldwide. Alterations in autonomic nervous system (ANS) activity contribute to cardiac disease progression, and the recent development of invasive techniques and electrical stimulation devices has opened new avenues for specific targeting of the sympathetic and parasympathetic branches of the ANS. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop which brought together clinicians, trialists and basic scientists to discuss the ANS as a therapeutic target in HF. The questions addressed were: (i) What are the abnormalities of ANS in HF patients? (ii) What methods are available to measure autonomic dysfunction? (iii) What therapeutic interventions are available to target the ANS in patients with HF, and what are their specific strengths and weaknesses? (iv) What have we learned from previous ANS trials? (v) How should we proceed in the future?Entities:
Keywords: Autonomic dysfunction; Devices and nerve ablation; Heart failure; Parasympathetic; Sympathetic
Mesh：
Year: 2017 PMID： 28949064 DOI： 10.1002/ejhf.921
Source DB: PubMed Journal: Eur J Heart Fail ISSN： 1388-9842 Impact factor: 15.534